RCUS
Price
$16.65
Change
+$1.34 (+8.75%)
Updated
Oct 4 closing price
30 days until earnings call
SNDX
Price
$18.82
Change
+$0.13 (+0.70%)
Updated
Oct 4 closing price
31 days until earnings call
Ad is loading...

RCUS vs SNDX

Header iconRCUS vs SNDX Comparison
Open Charts RCUS vs SNDXBanner chart's image
Arcus Biosciences
Price$16.65
Change+$1.34 (+8.75%)
Volume$648.65K
CapitalizationN/A
Syndax Pharmaceuticals
Price$18.82
Change+$0.13 (+0.70%)
Volume$559.82K
CapitalizationN/A
View a ticker or compare two or three
RCUS vs SNDX Comparison Chart
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
RCUS vs. SNDX commentary
Oct 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a StrongSell and SNDX is a StrongBuy.

COMPARISON
Comparison
Oct 07, 2024
Stock price -- (RCUS: $16.65 vs. SNDX: $18.82)
Brand notoriety: RCUS and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 109% vs. SNDX: 56%
Market capitalization -- RCUS: $1.41B vs. SNDX: $1.61B
RCUS [@Biotechnology] is valued at $1.41B. SNDX’s [@Biotechnology] market capitalization is $1.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 5 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).

  • RCUS’s TA Score: 5 bullish, 4 bearish.
  • SNDX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than SNDX.

Price Growth

RCUS (@Biotechnology) experienced а +8.05% price change this week, while SNDX (@Biotechnology) price change was -0.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

RCUS is expected to report earnings on Feb 19, 2025.

SNDX is expected to report earnings on Mar 05, 2025.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.61B) has a higher market cap than RCUS($1.41B). RCUS (-12.827) and SNDX (-12.911) have similar YTD gains . RCUS has higher annual earnings (EBITDA): -235M vs. SNDX (-263.84M). RCUS has more cash in the bank: 969M vs. SNDX (432M). SNDX has less debt than RCUS: SNDX (1.13M) vs RCUS (11M). RCUS has higher revenues than SNDX: RCUS (247M) vs SNDX (3.5M).
RCUSSNDXRCUS / SNDX
Capitalization1.41B1.61B88%
EBITDA-235M-263.84M89%
Gain YTD-12.827-12.91199%
P/E RatioN/AN/A-
Revenue247M3.5M7,057%
Total Cash969M432M224%
Total Debt11M1.13M973%
FUNDAMENTALS RATINGS
RCUS vs SNDX: Fundamental Ratings
RCUS
SNDX
OUTLOOK RATING
1..100
6113
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
7552
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5259
P/E GROWTH RATING
1..100
986
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (56) in the Pharmaceuticals Major industry is in the same range as SNDX (87) in the Biotechnology industry. This means that RCUS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (52) in the Biotechnology industry is in the same range as RCUS (75) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as SNDX (97) in the Biotechnology industry. This means that RCUS’s stock grew similarly to SNDX’s over the last 12 months.

RCUS's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as SNDX (59) in the Biotechnology industry. This means that RCUS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for RCUS (98) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew significantly faster than RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSSNDX
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
74%
N/A
View a ticker or compare two or three
Ad is loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KSDIX18.240.19
+1.05%
Keeley Small Cap Dividend Value I
NBGTX29.410.24
+0.82%
Neuberger Berman Large Cap Growth Tr
WPASX57.540.31
+0.54%
AB Concentrated Growth A
VETAX52.200.25
+0.48%
Victory Sycamore Established Value A
OIODX16.64-0.04
-0.24%
AXS Income Opportunities D

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with NTLA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+8.75%
NTLA - RCUS
53%
Loosely correlated
+1.93%
PRME - RCUS
51%
Loosely correlated
+2.93%
SNDX - RCUS
50%
Loosely correlated
+0.70%
OCUL - RCUS
50%
Loosely correlated
+6.61%
DNLI - RCUS
50%
Loosely correlated
+1.45%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with RCUS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+0.70%
RCUS - SNDX
51%
Loosely correlated
+8.75%
BPMC - SNDX
48%
Loosely correlated
+0.61%
FOLD - SNDX
48%
Loosely correlated
+0.38%
ALEC - SNDX
47%
Loosely correlated
+9.48%
ARVN - SNDX
46%
Loosely correlated
+1.96%
More